Download presentation
Presentation is loading. Please wait.
Published byClare Walters Modified over 9 years ago
1
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors by M. John Chapman, Wilfried Le Goff, Maryse Guerin, and Anatol Kontush EHJ Volume 31(2):149-164 January 14, 2010 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
2
Pathways of reverse cholesterol transport in man. M. John Chapman et al. Eur Heart J 2010;31:149-164 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
3
Comparison of pathways of cholesteryl ester transfer protein-mediated heterotransfer of neutral core lipids between lipoprotein particles in normotriglyceridaemia vs. mixed dyslipidaemia involving moderate to marked hypertriglyceridaemia and subnormal levels of triglyceride- enriched high-density lipoprotein. M. John Chapman et al. Eur Heart J 2010;31:149-164 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
4
Cardiovascular risk remains high despite aggressive statin therapy. M. John Chapman et al. Eur Heart J 2010;31:149-164 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.